1858 Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

1858 Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.39M	Buy	3,542 +1,079	+44%	+$451K	0.97%	32
2025 Q2	$1.1M	Sell	2,463 -375	-13%	-$173K	0.81%	34
2025 Q1	$1.38M	Buy	2,838 +54	+2%	+$25.2K	1.17%	26
2024 Q4	$1.12M	Buy	2,784 +165	+6%	+$76.5K	0.89%	31
2024 Q3	$1.22M	Sell	2,619 -43	-2%	-$20.7K	1%	27
2024 Q2	$1.25M	Sell	2,662 -252	-9%	-$109K	1.04%	31
2024 Q1	$1.19M	Hold	2,914	–	–	1.12%	25
2023 Q4	$1.19M	Buy	+2,914	New	+$1.08M	1.12%	25

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

1858 Wealth Management's VRTX Position: Q3 2025 in Review

1858 Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 44% in Q3 2025, buying an estimated $451K and bringing the position to 3,542 shares worth $1.39M. The position accounts for 0.97% of the portfolio, ranked #32.

1858 Wealth Management first reported a position in VRTX in Q4 2023 and has held it in 8 quarters since. 1,520 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

1858 Wealth Management held 3,542 shares of Vertex Pharmaceuticals worth $1.39M as of Q3 2025.
1858 Wealth Management bought 1,079 Vertex Pharmaceuticals shares in Q3 2025, an estimated $451K.
Vertex Pharmaceuticals made up 0.97% of 1858 Wealth Management's portfolio in Q3 2025, its #32 holding.
1858 Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
1,520 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on 1858 Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.